Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
ABIO's Cash to Debt is ranked higher than
91% of the 1484 Companies
in the Global Biotechnology industry.

( Industry Median: 48.31 vs. ABIO: No Debt )
ABIO' s 10-Year Cash to Debt Range
Min: 0.36   Max: No Debt
Current: No Debt

F-Score: 3
Z-Score: -1.28
M-Score: -3.86
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE (%) -59.14
ABIO's ROE (%) is ranked higher than
63% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: -28.35 vs. ABIO: -59.14 )
ABIO' s 10-Year ROE (%) Range
Min: -828.55   Max: -17.89
Current: -59.14

-828.55
-17.89
ROA (%) -55.41
ABIO's ROA (%) is ranked higher than
60% of the 1489 Companies
in the Global Biotechnology industry.

( Industry Median: -22.44 vs. ABIO: -55.41 )
ABIO' s 10-Year ROA (%) Range
Min: -134.31   Max: -8.06
Current: -55.41

-134.31
-8.06
ROC (Joel Greenblatt) (%) -33268.21
ABIO's ROC (Joel Greenblatt) (%) is ranked lower than
52% of the 1448 Companies
in the Global Biotechnology industry.

( Industry Median: -352.58 vs. ABIO: -33268.21 )
ABIO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -29824.62   Max: -42.86
Current: -33268.21

-29824.62
-42.86
EBITDA Growth (3Y)(%) -45.10
ABIO's EBITDA Growth (3Y)(%) is ranked higher than
56% of the 851 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. ABIO: -45.10 )
ABIO' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -73.4   Max: 17.3
Current: -45.1

-73.4
17.3
EPS Growth (3Y)(%) -47.30
ABIO's EPS Growth (3Y)(%) is ranked higher than
55% of the 819 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. ABIO: -47.30 )
ABIO' s 10-Year EPS Growth (3Y)(%) Range
Min: -72.5   Max: 24.5
Current: -47.3

-72.5
24.5
» ABIO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

ABIO Guru Trades in Q2 2013

Jim Simons 14,800 sh (+3.27%)
» More
Q3 2013

ABIO Guru Trades in Q3 2013

Jim Simons 93,770 sh (+533.58%)
» More
Q4 2013

ABIO Guru Trades in Q4 2013

Jim Simons 615,182 sh (+556.05%)
» More
Q1 2014

ABIO Guru Trades in Q1 2014

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ABIO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.70
ABIO's P/B is ranked higher than
94% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 6.60 vs. ABIO: 1.70 )
ABIO' s 10-Year P/B Range
Min: 0.01   Max: 14.78
Current: 1.7

0.01
14.78
EV-to-EBIT -0.56
ABIO's EV-to-EBIT is ranked higher than
71% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ABIO: -0.56 )
ABIO' s 10-Year EV-to-EBIT Range
Min: -10.5   Max: 2.2
Current: -0.56

-10.5
2.2
Current Ratio 11.19
ABIO's Current Ratio is ranked higher than
88% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. ABIO: 11.19 )
ABIO' s 10-Year Current Ratio Range
Min: 0.22   Max: 27.54
Current: 11.19

0.22
27.54
Quick Ratio 11.19
ABIO's Quick Ratio is ranked higher than
89% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. ABIO: 11.19 )
ABIO' s 10-Year Quick Ratio Range
Min: 0.22   Max: 27.54
Current: 11.19

0.22
27.54

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.50
ABIO's Price/Net Cash is ranked higher than
98% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 220.30 vs. ABIO: 1.50 )
ABIO' s 10-Year Price/Net Cash Range
Min: 0.66   Max: 285.92
Current: 1.5

0.66
285.92
Price/Net Current Asset Value 1.50
ABIO's Price/Net Current Asset Value is ranked higher than
98% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 46.00 vs. ABIO: 1.50 )
ABIO' s 10-Year Price/Net Current Asset Value Range
Min: 0.65   Max: 144.03
Current: 1.5

0.65
144.03
Price/Tangible Book 1.40
ABIO's Price/Tangible Book is ranked higher than
95% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 10.40 vs. ABIO: 1.40 )
ABIO' s 10-Year Price/Tangible Book Range
Min: 0.53   Max: 39.01
Current: 1.4

0.53
39.01
Earnings Yield (Greenblatt) -194.90
ABIO's Earnings Yield (Greenblatt) is ranked lower than
70% of the 1445 Companies
in the Global Biotechnology industry.

( Industry Median: -5.60 vs. ABIO: -194.90 )
ABIO' s 10-Year Earnings Yield (Greenblatt) Range
Min: -197.5   Max: 4864.2
Current: -194.9

-197.5
4864.2

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:HQ13.Germany,
ARCA biopharma, Inc., was originally incorporated as Hyseq, Inc. in Illinois in 1992 and reincorporated in Nevada in 1993. On January 31, 2003, Nuvelo merged with Variagenics, Inc., a publicly traded Delaware corporation based in Massachusetts, and, in connection with the merger, changed its name to Nuvelo, Inc. On March 25, 2004, it was reincorporated from Nevada to Delaware. On January 27, 2009, in connection with the Merger with ARCA Colorado described above, Nuvelo changed its name to ARCA biopharma, Inc. Its main offices are located in Broomfield, Colorado. It is a biopharmaceutical company whose focus is developing genetically-targeted therapies for cardiovascular diseases. Its product candidate, Gencaro TM (bucindolol hydrochloride), a pharmacologically unique beta-blocker and mild vasodilator, is being developed for the treatment of atrial fibrillation (AF) in patients with heart failure (HF). The company has been granted patents in the U.S., Europe, and other jurisdictions for methods of treating AF and HF patients with Gencaro based on genetic testing. The company outsources all manufacturing and analytical testing of the Gencaro API and drug product. The company is contracted with Groupe Novasep to complete the drug substance registration batches required for the Gencaro NDA. These batches were successful, and the resulting drug substance was used to supply the drug product registration campaign. For drug product production, the company has contracted with Patheon, Inc. to manufacture the Gencaro tablets. Gencaro is produced in a tablet form, utilizing standard solid oral dosage processing techniques. The Company faces competition from pharmaceutical companies and biotechnology companies that are researching and selling products designed to treat cardiovascular conditions. Governmental authorities in the U.S. at the federal, state, and local levels and foreign countries regulate, among other things, the research, development, testing, manufacture, labeling, promotion, advertising, marketing, distribution, sampling, and import and export of pharmaceutical and medical device products.
» More Articles for ABIO

Headlines

Articles On GuruFocus.com
comment on ABIO Mar 15 2013 
ARCA BIOPHARMA, INC. Reports Operating Results (10-Q) Nov 15 2010 
ARCA BIOPHARMA, INC. Reports Operating Results (10-Q) Aug 10 2010 
ARCA BIOPHARMA, INC. Reports Operating Results (10-Q) May 10 2010 
ARCA BIOPHARMA, INC. Reports Operating Results (10-Q) Nov 16 2009 
ARCA BIOPHARMA, INC. Reports Operating Results (10-Q) Aug 10 2009 
ARCA biopharma Inc. Reports Operating Results (10-Q) May 15 2009 
ARCA biopharma Inc. Reports Operating Results (10-Q) Feb 07 2009 

More From Other Websites
ARCA BIOPHARMA, INC. Financials May 22 2015
10-Q for ARCA biopharma, Inc. May 14 2015
ARCA BIOPHARMA, INC. Files SEC form 10-Q, Quarterly Report May 12 2015
10-K for ARCA biopharma, Inc. May 02 2015
ARCA biopharma Gains on Fast Track Status for Gencaro - Analyst Blog Apr 14 2015
ARCA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 13 2015
ARCA biopharma (ABIO) Stock Surges Today on FDA Fast Track Designation Apr 13 2015
ARCA biopharma Receives FDA Fast Track Designation for Gencaro™ Atrial Fibrillation Development in... Apr 13 2015
ARCA biopharma Provides GENETIC-AF Clinical Trial Update Mar 20 2015
ARCA BIOPHARMA, INC. Files SEC form 10-K, Annual Report Mar 19 2015
ARCA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 16 2015
ARCA biopharma Provides GENETIC-AF Clinical Trial Update Mar 16 2015
3 Biotech stocks Under $10 to Trade for Breakouts Mar 05 2015
ARCA BIOPHARMA, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued... Feb 23 2015
ARCA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers Feb 17 2015
ARCA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Feb 04 2015
ARCA biopharma Announces Patent Issuance for Methods and Compositions of S-isomer Formulation of... Feb 04 2015
ARCA BIOPHARMA, INC. Files SEC form 8-K/A, Change in Directors or Principal Officers, Financial... Dec 30 2014
ARCA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 11 2014
Arca biopharma Announces Activation of First Canadian Genetic-AF Clinical Trial Site Dec 11 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK